4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      New 1 H-Benzo[ f]indazole-4,9-diones Conjugated with C-Protected Amino Acids and Other Derivatives: Synthesis and in Vitro Antiproliferative Evaluation

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          1 H-Benzo[ f]indazole-4,9-dione derivatives conjugated with C-protected amino acids (glycine, l-alanine, l-phenylalanine and l-glutamic acid) 6al were prepared by chemically modifying the prenyl substituent of 3-methyl-7-(4-methylpent-3-enyl)-1 H-benzo[ f]indazole-4,9-dione 2 through epoxidation, degradative oxidation, oxidation and N-acyl condensation reactions. The chemical structures of the synthesized compounds were elucidated by analyzing their IR, 1H-NMR and 13C-NMR spectral data together with elemental analysis for carbon, hydrogen and nitrogen. The preliminary in vitro antiproliferative activity of the synthesized derivatives was evaluated on KATO-III and MCF-7 cell lines using a cell proliferation assay. The majority of the derivatives exhibited significant antiproliferative activity with IC 50 values ranging from 25.5 to 432.5 μM. These results suggest that 1 H-benzo[ f]indazole-4,9-dione derivatives are promising molecules to be researched for developing new anticancer agents.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.

          Although patients with advanced refractory solid tumors have poor prognosis, the clinical development of targeted protein kinase inhibitors offers hope for the future treatment of many cancers. In vivo and in vitro studies have shown that the oral multikinase inhibitor, sorafenib, inhibits tumor growth and disrupts tumor microvasculature through antiproliferative, antiangiogenic, and/or proapoptotic effects. Sorafenib has shown antitumor activity in phase II/III trials involving patients with advanced renal cell carcinoma and hepatocellular carcinoma. The multiple molecular targets of sorafenib (the serine/threonine kinase Raf and receptor tyrosine kinases) may explain its broad preclinical and clinical activity. This review highlights the antitumor activity of sorafenib across a variety of tumor types, including renal cell, hepatocellular, breast, and colorectal carcinomas in the preclinical setting. In particular, preclinical evidence that supports the different mechanisms of action of sorafenib is discussed.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Numerical integration for polyatomic systems

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              The determination of molecular structures by density functional theory. The evaluation of analytical energy gradients by numerical integration

                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Molecules
                Molecules
                molecules
                Molecules
                MDPI
                1420-3049
                08 December 2015
                December 2015
                : 20
                : 12
                : 21924-21938
                Affiliations
                [1 ]Instituto de Química, Facultad de Ciencias, Pontificia Universidad Católica de Valparaíso, Valparaíso 2373223, Chile; m.arismendi.m@ 123456gmail.com (M.A.-M.); leda.guzman@ 123456ucv.cl (L.G.); mauricio.fuentealba@ 123456ucv.cl (M.F.); marcela.knox@ 123456gmail.com (M.K.)
                [2 ]Facultad de Farmacia, Universidad de Valparaíso, Valparaíso 2360102, Chile; raul.vinet@ 123456uv.cl
                [3 ]Centro Regional de Estudios en Alimentos y Salud (CREAS), Valparaíso 2362696, Chile
                [4 ]Facultad de Farmacia, Departamento de Química Farmacéutica, CIETUS, IBSAL, Universidad de Salamanca, Salamanca 37007, Spain; asf@ 123456usal.es
                Author notes
                [* ]Correspondence: amolinar@ 123456ucv.cl (A.M.); aoliva@ 123456ucv.cl (A.O.); Tel.: +56-032-227-4938 (A.M.); Fax: +56-032-227-4910 (A.M.)
                Article
                molecules-20-19809
                10.3390/molecules201219809
                6332180
                26670225
                c7fb6100-4447-48f2-b5c9-2fba940a6f64
                © 2015 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 04 November 2015
                : 01 December 2015
                Categories
                Article

                1,4-naphthoquinone,1h-benzoindazole,pyrazole,amino acid
                1,4-naphthoquinone, 1h-benzoindazole, pyrazole, amino acid

                Comments

                Comment on this article